Sensory Bridges Roadmap

Education-first launch with a clear path to clinical and medical channels — building proof, credibility, and data at every stage.

Education Entry Clinical Expansion Medical Pathway

The Path at a Glance

🏫
2026
🩺
2027
🏥
2028
💳
2029
🚀
2030+
📊
📄
🔬
✅
🌐
⌚
🏫
🏥
💳
📊

The Strategic Question

Should Sensory Bridges bypass education and go directly to major autism centers with a clinical-first approach? This roadmap shows why education is the proof-of-concept engine that makes the clinical pathway actually work — and that clinical expansion is already baked into the plan starting in Year 2.

Why Education First

Schools buy with IDEA Part B funding that already exists. No FDA clearance required. Faster sales cycles. Product generates the outcome data and IEP documentation proof that clinical partners will demand before they say yes. Education is the proof-of-concept engine.

Why Clinical Is Already In the Plan

The clinical-first instinct is right — clinical/medical channels unlock bigger contracts and legitimacy. The business model already includes OT/therapy network sales starting Year 1, Medicaid waiver research starting Year 2, and a full clinical reimbursement pathway by Year 4. Education builds the evidence; clinical scales the revenue.

The Roadmap: Education → Clinical → Medical

Five phases showing how each stage builds the foundation for the next.

1
Phase 1 — Education Beachhead
Paid Pilots & Proof of Concept
Now → End of 2026 (Months 1–12)
What's Happening 5–8 paid school district pilots at $5K–$10K each. Product positioned as assistive technology (IDEA) — not medical. Funded through existing IDEA Part B budgets.
Why It Matters Every pilot generates real outcome data (behavioral incident reduction, IEP progress). This is the clinical evidence that autism centers will require before signing anything.
Clinical Seed Planting 8–10 OT practices get free device trials and structured data collection agreements. These become clinical champions who later drive referrals.
Key Milestones Hire Clinical Outcomes Lead. Submit first IRB protocol. First case study submitted to peer-reviewed OT journal. $350K ARR target.
2
Phase 2 — Institutional Scale + Clinical Entry
District Contracts & Therapy Network Sales
2027 (Months 13–24)
Education Channel 15 district contracts at $60K average ACV. First enterprise sales hire. Expansion revenue from Year 1 accounts (NRR 130%+). State education agency partnerships begin.
Clinical Channel Opens 25 OT/ABA therapy network accounts at $18K average ACV. Therapy practices paying from operational budgets — no grant dependency. Insurance documentation toolkit add-on launched.
Evidence Building First peer-reviewed outcomes publication. Case series across 5–10 sites. Begin Medicaid EPSDT eligibility research in 2 states. IES grant application submitted.
Key Milestones Pre-seed close ($750K–$1M). Published clinical evidence. Medicaid conversations initiated. $1.4M ARR target.
⟶

The Pivot Point: Education Data Unlocks Clinical Credibility

By the end of Phase 2, Sensory Bridges has something no competitor can claim: peer-reviewed outcome data from real school deployments, a proprietary behavioral metric embedded in IEP documents, and 40+ institutional accounts proving market demand. This is exactly the proof of concept that makes the clinical approach viable — not aspirational. Without this data, approaching top clinical centers is premature. With it, you arrive with evidence, not just a pitch.

3
Phase 3 — Clinical Acceleration
Autism Centers & Medical Advisory Board
2028 (Months 25–36)
Major Center Partnerships Partner with 5–10 major autism/neurodevelopment centers nationally. Built on 2 years of published data and OT network referrals. Announce Medical Advisory Board (5 distinguished leaders in autism care).
Hardware Partnership Leverage Announce the B2B hardware relationship formally. Major consumer technology platform partnership is now public-facing, lending institutional credibility to every clinical conversation.
Data Collection at Scale First 2,500 device rollout to dedicated clinical centers. Structured feedback loop: What works? What doesn't? What needs to change? Product refinement powered by 2 years of prior real-world school iteration.
Key Milestones Series A close ($6M–$10M). Multi-site prospective study. Medicaid waiver applications active in 2–3 states. CPT code advocacy begins. $3.5M+ ARR target.
4
Phase 4 — Reimbursement & Medical Integration
Medicaid Coverage & Prescriber Network
2029 (Months 37–48)
Medicaid Pathway Medicaid EPSDT coverage approved in 1–2 states. Device costs families nothing — state Medicaid pays. This is the game-changer: removes all price friction from the buyer.
Prescriber Network OTs and SLPs can now prescribe the device through insurance channels. Building the same reimbursement navigation infrastructure that made Tobii Dynavox a publicly traded company.
Education + Clinical Flywheel Schools generate data → clinical centers validate outcomes → insurance covers the device → more schools adopt because families can get it covered → more data flows in. Self-reinforcing loop.
Key Milestones 80+ institutional accounts. NRR 120%+. 2+ peer-reviewed publications. $10M–$15M ARR. Series B from position of strength.
5
Phase 5 — Full Medical Platform (Optional)
FDA Clearance & National Reimbursement
2030+ (Months 49+)
FDA Decision Point With 4+ years of clinical data, published outcomes, and Medicaid coverage in multiple states, FDA De Novo clearance becomes a strategic option — not a survival requirement. This is the "digital therapeutics" pathway, entered from a position of revenue strength.
National Scale State-level population health contracts. National reimbursement across all 50 states. $50M–$150M ARR ceiling as EdTech platform; $200M–$500M ceiling if full medical reimbursement is achieved.
The Data Moat Years of proprietary behavioral data across thousands of neurodivergent students — a dataset no competitor can replicate. Research partnerships with academic medical centers. Pharmaceutical companies paying for access to de-identified behavioral data.
The Full Vision Realized Legitimacy. B2B partnership. Medical board. National center partnerships. Data-driven product refinement. Proof of concept proven. All achieved — built on a foundation of education revenue rather than clinical speculation.

Revenue Mix Shifts from Education to Clinical Over Time

2026
~$350K
2027
~$1.4M
2028
~$3.5M
2029
~$10M+
2030+
$50M–$150M+
Education (Districts / IDEA)
Clinical & Medical (Therapy / Medicaid / Insurance)

Mapping the Clinical-First Approach to This Roadmap

Every element of the clinical-first vision is in the plan — the question is timing and sequence.

Announce B2B hardware partnership Phase 3 (2028) — after embargo lifts and education traction proves market. Announcing too early without revenue creates a "so what?" from clinical buyers.
Partner with top autism centers Phase 3 (2028) — but seeded by OT clinical champions recruited in Phase 1. By 2028, you approach centers with published data, not just a prototype.
Medical Advisory Board (5 leaders) Phase 3 (2028) — formalize the advisory board with distinguished autism care leaders. This follows the Wearable Devices playbook already in the strategy.
Roll out 2,500 bands to centers Phase 3 (2028) — funded by Series A ($6M–$10M), not pre-seed. Deploying 2,500 units requires manufacturing capital that doesn't exist pre-revenue.
Collect data and learn Every phase — data collection starts Day 1 in schools, not in Phase 3. By the time autism centers get devices, the product has already been refined through 2 years of real-world deployment.
Why not skip straight to clinical? Clinical centers require published evidence, IRB-approved protocols, and HIPAA compliance. Schools operate under FERPA (simpler), buy with existing budgets (IDEA), and don't require FDA positioning. Education is faster to revenue and generates the proof clinical needs.